---
title: Activity and safety of avelumab in high-grade neuroendocrine tumors and poorly
  differentiated neuroendocrine carcinomas progressive after chemotherapy (AveNEC
  trial)
date: '2025-01-09'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/39786465/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20250109170938&v=2.18.0.post9+e462414
source: heidelberg[Affiliation]
description: 'CONCLUSIONS: In patients with progressive high-grade NEN G3, avelumab
  was well tolerated and provided disease control with significant clinical benefit
  in 15% of heavily pretreated ...'
disable_comments: true
---
CONCLUSIONS: In patients with progressive high-grade NEN G3, avelumab was well tolerated and provided disease control with significant clinical benefit in 15% of heavily pretreated ...